“An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis”, J of Skin, vol. 4, no. 5, p. s27, Sep. 2020, doi: 10.25251/skin.4.supp.27.